Which Is Safer, Chinese Medicine or Western Medicine?Comparative Analysis Based on Chinese Spontaneous Reporting Database

Jian-xiang WEI; Zhi-qiang LU; Guan-zhong FENG; Yun-xia ZHU

doi:10.1007/s11655-021-3340-7

Your Location：

Home >

Browse articles >

Which Is Safer, Chinese Medicine or Western Medicine?Comparative Analysis Based on Chinese Spontaneous Reporting Database

Original Article | Updated：2022-02-22

- Which Is Safer, Chinese Medicine or Western Medicine?Comparative Analysis Based on Chinese Spontaneous Reporting Database
- Chinese Journal of Integrative Medicine Vol. 28, Issue 2, Pages: 138-144(2022)
- Affiliations：
  
  1.School of Management, Nanjing University of Posts and Telecommunications, Nanjing (210003), China
  2.School of Internet of Things, Nanjing University of Posts and Telecommunications, Nanjing (210003), China
- Author bio：
  
  Associate Prof. WEI Jian-xiang, E-mail:jxwei@njupt.edu.cn
- Funds：
- DOI：10.1007/s11655-021-3340-7
  CLC：
- Published：01 February 2022，
  
  Published Online：01 October 2021，
  
  Accepted：08 January 2021
Scan for full text
Jian-xiang WEI, Zhi-qiang LU, Guan-zhong FENG, et al. Which Is Safer, Chinese Medicine or Western Medicine?Comparative Analysis Based on Chinese Spontaneous Reporting Database. [J]. Chinese Journal of Integrative Medicine 28(2):138-144(2022)
DOI：

Jian-xiang WEI, Zhi-qiang LU, Guan-zhong FENG, et al. Which Is Safer, Chinese Medicine or Western Medicine?Comparative Analysis Based on Chinese Spontaneous Reporting Database. [J]. Chinese Journal of Integrative Medicine 28(2):138-144(2022) DOI： 10.1007/s11655-021-3340-7.

摘要

目的:

基于中国自发报告数据库比较中药和西药之间的安全性差异.

方法:

以2010年至2011年中国自发报告数据库中中药和西药引起的不良事件报告为研究数据. 构建了以下评价指标: 严重不良事件比例 (PSE) 、平均不良事件数 (ANA) 和不良事件覆盖率 (CRA) . 进一步的安全性比较还包括报告不良事件最多的药物

报告数量最多的不良事件

以及5种感兴趣的严重不良事件 (包括死亡、过敏性休克、昏迷、呼吸困难和肝功能异常) .

结果:

西药的PSE、ANA和CRA分别是中药的1.09、8.23和2.35倍. 最严重不良事件的前10名药物主要是中药注射剂和西药抗生素. 两者不良事件报告数量最多的是皮疹、瘙痒、恶心、头晕和呕吐

在过敏性休克和昏迷中的比例两者相似

而对于肝功能异常和死亡

西药的比例则分别是中药的5.47倍和3.00倍.

结论:

基于中国自发报告数据库

从药物不良反应的视角

中药在平均水平上比西药更加安全.

Abstract

Objective:

To compare the safety differences between Chinese medicine (CM) and Western medicine (WM) based on Chinese Spontaneous Reporting Database (CSRD).

Methods:

Reports of adverse events (AEs) caused by CM and WM in the CSRD between 2010 and 2011 were selected. The following assessment indicators were constructed: the proportion of serious AEs (PSE)

the average number of AEs (ANA)

and the coverage rate of AEs (CRA). Further comparisons were also conducted

including the drugs with the most reported serious AEs

the AEs with the biggest report number

and the 5 serious AEs of interest (including death

anaphylactic shock

coma

dyspnea and abnormal liver function).

Results:

The PSE

ANA and CRA of WM were 1.09

8.23 and 2.35 times higher than those of CM

respectively. The top 10 drugs with the most serious AEs were mainly injections for CM and antibiotics for WM. The AEs with the most reports were rash

pruritus

nausea

dizziness and vomiting for both CM and WM. The proportions of CM and WM in anaphylactic shock and coma were similar. For abnormal liver function and death

the proportions of WM were 5.47 and 3.00 times higher than those of CM

respectively.

Conclusion:

Based on CSRD

CM was safer than WM at the average level from the perspective of adverse drug reactions.

关键词

Keywords

Chinese medicineWestern medicinedata analysisadverse drug reactiondrug safety

references

Zhang L, Yan J, Liu X, Ye Z, Yang X, Meyboom R, et al.Pharmacovigilance practice and risk control of traditional Chinese medicine drugs in China: current status and future perspective. J Ethnopharmacol 2012;140:519-525.

Gyamfi ET. Assessment of essential and non-essential elements in selected traditional medicines from India,Ghana and China. Environm Sci Pollut Res 2020;28:1-11.

Gyamfi ET. Metals and metalloids in traditional medicines (Ayurvedic medicines, nutraceuticals and traditional Chinese medicines). Environ Sci Pollut Res Int 2019;26:15767-15778.

Wiebrecht A, Gaus W, Becker S, Hummelsberger J,Kuhlmann K. Safety aspects of Chinese herbal medicine in pregnancy—re-evaluation of experimental data of two animal studies and the clinical experience. Complement Therap Med 2014;22:954-964.

Fung FY, Linn YC. Developing traditional Chinese medicine in the era of evidence-based medicine: current evidences and challenges. Evid Based Complement Alternat Med 2015;2015:425037.

Chung VC, Ma PH, Lau CH, Wong SY, Yeoh EK, Griffiths SM. Views on traditional Chinese medicine amongst Chinese population: a systematic review of qualitative and quantitative studies. Health Expectat 2014;17:622-636.

Park J, Park HJ, Lee HJ, Ernst E. What's in a name? A systematic review of the nomenclature of Chinese medical formulae. Am J Chin Med 2008;30:419-427.

Vetter N, Vetter D. Traditional Chinese medicine—is the grass always greener? J Public Health 2007;29:1-2.

Kong DX, Li XJ, Tang GY, Zhang HY. How many traditional Chinese medicine components have been recognized by modern Western medicine? A chemoinformatic analysis and implications for finding multicomponent drugs.Chemmedchem 2010;3:233-236.

Barnes J. Pharmacovigilance of herbal medicines: a UK perspective. Drug Safety 2003;26:829-851.

Fleischer T, Su Y, Lin SJ. How do government regulations influence the ability to practice Chinese herbal medicine in Western countries. J Ethnopharmacol 2017;196:104-109.

Green G, Bradby H, Chan A, Lee M. "We are not completely westernised": dual medical systems and pathways to health care among Chinese migrant women in England. Soc Sci Mede 2006;62:1498-1509.

Lai DW, Chappell NL. Use of traditional Chinese medicine by older Chinese immigrants in Canada. Family Pract 2006;24:56-64.

Xiao E and Luo L. Alternative therapies for diabetes: a comparison of Western and traditional Chinese medicine(TCM) approaches. Curr Diabetes Rev 2018;14:487-496.

Min LI, Kun MA. Comparative study of embryonic diapauses prevention in Western medicine and traditional Chinese medicine. China J Chin Mater Med 2014;39:1132-1135.

Gao L, Wu X. Comparison of traditional Chinese medicine with Western medicine cancer therapy. Clin Oncol Cancer Res 2008;5:231-234.

Song Y, Ruan Z, Yin S, Bian Y. Comparison of risks for adverse drug reactions between traditional Chinese medicines and Western medicines: a review of Chinese-language literatures.Afr J Tradit Complement Alternat Med 2015;12:53-62.

Esterhuizen TM, Thabane L. Con: meta-analysis: some key limitation and potential solutions. Nephrol Dialysis Transplant 2016;31:882-885.

Delgado-Rodriguez M. Systematic reviews of meta-analyses: applications and limitations. J Epidemiol Commun Health 2006;60:90-92.

Lyman GH, Kuderer NM. The strengths and limitations of meta-analyses based on aggregate data. BMC Med Res Methodol 2005;5:14.

Li HN, Deng JX, Deng LW, Ren XQ, Xia JL. Safety profile of traditional Chinese herbal injection: an analysis of a spontaneous reporting system in China. Pharmacoepidemiol Drug Saf 2019;28:1002-1013.

Li HN, Wang SW, Yue ZH, Ren XQ, Xia JL. Traditional Chinese herbal injection: current status and future perspectives. Fitoterapia 2018;129:249-256.

Tan L, Li M, Lin Y. Safety Concerns of traditional Chinese medicine injections used in Chinese children. Evid Based Complement Alternat Med 2019;2019:1-10.

CFDA. Adverse Drug Reactions Bulletin (No.21): alerting serious adverse reactions of cefoperazone sulbactam sodium and Qingkailing Injection. Accessed April 20,2009. Available at https://www.nmpa.gov.cn/xxgk/yjjsh/ypblfytb/20090420120001639.htmlhttps://www.nmpa.gov.cn/xxgk/yjjsh/ypblfytb/20090420120001639.html

CFDA. Adverse Drug Reactions Bulletin (No.45): Alerting serious adverse reactions of Xiangdan Injection. Accessed March 23, 2012. Available at https://www.nmpa.gov.cn/xxgk/yjjsh/ypblfytb/20120323162201191.htmlhttps://www.nmpa.gov.cn/xxgk/yjjsh/ypblfytb/20120323162201191.html

CFDA. Adverse Drug Reactions Bulletin (No.48): Alerting serious allergic reaction of Mailuoning Injection. Accessed June 25, 2012. Available at https://www.nmpa.gov.cn/xxgk/yjjsh/ypblfytb/20120625164401325.htmlhttps://www.nmpa.gov.cn/xxgk/yjjsh/ypblfytb/20120625164401325.html

CFDA. Adverse Drug Reactions Bulletin (No.56): alerting serious adverse reactions of levofloxacin injection.Accessed August 2, 2013. Available at https://www.nmpa.gov.cn/xxgk/yjjsh/ypblfytb/20130802184601656.htmlhttps://www.nmpa.gov.cn/xxgk/yjjsh/ypblfytb/20130802184601656.html

The general office of the Ministry of Health. Notice on strengthening the clinical use and management of clindamycin injection. Accessed July 3, 2009. Available at http://www.nhc.gov.cn/yzygj/s3585u/200907/7bc4c3f8ac914d1695982b25f634caa0.shtmlhttp://www.nhc.gov.cn/yzygj/s3585u/200907/7bc4c3f8ac914d1695982b25f634caa0.shtml

Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol 2017;35:605-612.

Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354:731-739.

Zhang XD, Han L, Zhu FP. Considerations for current evaluation for nonclinical safety of compound preparations from traditional Chinese medicine. Chin J New Drug 2009;18:1294-1296.

Tailor A, Faulkner L, Naisbitt D, Park B. The chemical,genetic and immunological basis of idiosyncratic drug-induced liver injury. Hum Exp Toxicol 2015;34:1310-1317.

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Treatment Progress in Diminished Ovarian Reserve: Western and Chinese Medicine

Combination of Chinese and Western Medicine to Prevent and Reverse Resistance of Cancer Cells to Anticancer Drugs

Progress in Treatment of Gout Using Chinese and Western Medicine

New Concept of Health with Perspective of Chinese Medicine

Related Author

No data

Related Institution

Department of Human Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital

Department of Encephalopathy, Shaanxi Provincial Hospital of Chinese Medicine

Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University

Key Laboratory of Elemene Class Anti-cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰